Add to My Stocks
$215.76 $8.46 (4.08%) MDGL stock closing price Sep 19, 2018 (Closing)

The MADRIGAL PHARMA cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. This statement shows details about the cash generated and spent during a particular quarter, while the other two statements give details about MADRIGAL PHARMA profits and MADRIGAL PHARMA debt. MADRIGAL PHARMA cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. MADRIGAL PHARMA had cash and cash equivalents of $148.63M at the beginning of the quarter and $264.86M at quarter end for 2018 Q2. MADRIGAL PHARMA saw a outflow of $-183.04M from investing activities till 2018 Q2.

View and download details of MADRIGAL PHARMA cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow----------
Net Increase (Decrease) in Assets Liabilities-4.62M-3.47M5.5M4.01M1.63M1.62M-1.1M-2.99M-10.42M-6.18M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net3.39M1.16M3.25M2.3M1.27M-9.88M9.3M--
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment---0.12M-0.12M-0.12M-----
Acquisition Disposition of Subsidiaires------5.84M5.84M--
Increase (Decrease) in Investments-183.04M-102.12M-21.88M-27.96M-11.08M-10.55M15.36M5.58M-0.57M22.38M
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares313.27M-173.8M38.27M38.27M3.39M5.95M---
Issuance (Repayment) of Debt Securities------8.5M8.5M-4.61M-2.31M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year148.63M19.14M-46.02M48.49M81.51M30.07M31.31M44.15M52.04M
Cash & Equivalents at Year End264.86M38.12M148.62M12.96M34.79M8.21M19.14M8.39M10.75M42.81M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The MADRIGAL PHARMA stock price history and MADRIGAL PHARMA stock comparison chart inevitably reflect its cash flow situation.

  • MADRIGAL PHARMA saw a positive change in Net Change in Cash and Cash Equivalents of $116.23M till 2018 Q2. Apart from the MADRIGAL PHARMA stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • MADRIGAL PHARMA decreased its cash from operating activities to $-14M till 2018 Q2. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash from investing stood at a negative value of $-183.04M for MDGL stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $313.27M for MADRIGAL PHARMA.

Key Financial Ratios For MADRIGAL PHARMA Cash Flow

FCF margin